Strides Pharma Secures Notable Gains Following US FDA Approval of Hypocalcemia Treatment

Strides Pharma experienced a notable surge in stock prices, climbing 3.20% to reach an intraday peak of Rs 858.10 on Friday. This uptick was spurred by the U.S. Food and Drug Administration’s approval of its Sevelamer carbonate tablets, a significant development in the treatment of Hypocalcemia, associated with chronic kidney disease.

The approved Sevelamer Carbonate 800 mg tablets are designed to control elevated phosphate levels in the bloodstream, a common issue for those suffering from chronic kidney conditions. This product is both bioequivalent and therapeutically equivalent to the Reference Listed Drug, Renvela tablets, which are also 800 mg and produced by Genzyme.

This approval not only boosts Strides Pharma’s portfolio but also taps into a substantial market, with the Sevelamer product line including both tablets and oral suspension powder. According to IMS data, the tablet market alone is estimated to be worth $181 million, with the oral suspension powder targeting an additional $23 million market.

Strides Pharma will manufacture the Sevelamer tablets at its Puducherry facility, one of its numerous manufacturing sites spread across four continents. The company’s global operations include eight manufacturing facilities, five of which are FDA-approved and located in the United States. The company also maintains facilities in Chennai, two in Bengaluru, as well as international sites in Milan, Nairobi, and New York.

Furthermore, Strides Pharma, headquartered in Bengaluru, continues to expand its global presence in both regulated and emerging markets. With a total of 260 cumulative abbreviated new drug application (ANDA) filings with the US FDA, over 245 have already been approved. Additionally, the company recently expanded its portfolio through the acquisition of assets from Endo at Chestnut Ridge, reinforcing its competitive edge in the pharmaceutical industry.

As part of its ambitious growth strategy, Strides Pharma has outlined plans to launch around 60 new products in the US market over the next three years. This aggressive expansion underscores the company’s commitment to enhancing its product offerings and securing a stronger foothold in the competitive pharmaceutical sector.

By the afternoon trading session, Strides Pharma’s shares were up by 1.59% at Rs 844.70, outperforming the S&P BSE Sensex, which saw a modest increase of 0.04% to 72,434.47.

Key Takeaways

  • Strides Pharma received approval from the US FDA for its Sevelamer Carbonate tablets used in treating Hypocalcemia in chronic kidney disease patients.
  • The company capitalized on this opportunity, addressing a combined market potential of over $200 million for its Sevelamer products.
  • Manufacturing will take place in Strides Pharma’s Puducherry facility, part of a vast global manufacturing network.
  • Strides Pharma plans to introduce approximately 60 new products in the US within the next three years, demonstrating its robust growth strategy.

Conclusion

The recent FDA approval represents a significant milestone for Strides Pharma, not only enhancing its product portfolio but also solidifying its market position in the pharmaceutical industry. This development promises substantial growth prospects and is expected to contribute positively to the company’s performance in the coming years. As Strides Pharma continues to expand and innovate, it remains poised for further success in a competitive global market.


SPONSORED AD

Mondays are the worst

Mondays are tough. After a weekend of fun, that alarm feels early. Imagine having something to look forward to. Extra income, maybe? My Weekend Gold Rush can help! With the new market paradigm this week, now is the perfect time.

Earn While the Market Rests

Don’t wait. Discover Weekend Gold Rush now!

OUR TRADING BRANDS

LATEST POSTS

This Publication is part of Anchor IR

Trading foreign exchange, stocks, options, or futures on margin carries a high level of risk, and may not be suitable for all investors. Before deciding to trade, you should carefully consider your objectives, financial situation, needs and level of experience. Pharma Stocks Today provides general advice that does not take into account your objectives, financial situation or needs. The content of this website must not be construed as personal advice. The possibility exists that you could sustain a loss in excess of your deposited funds and therefore, you should not speculate with capital that you cannot afford to lose. You should be aware of all the risks associated with trading on margin. You should seek advice from an independent financial advisor. Past performance is not necessarily indicative of future success

United States Post Office. P.O. Box 184 500 Venetia Rd. Pennsylvania 15367-999

PharmaStocksToday.com is copyright (© 2024) of Anchor IR. All Rights Reserved